Participants have received ontamalimab at the maintenance study ET or Week 52 Received ontamalimab in the induction study and fulfilled the maintenance study Responded to ontamalimab treatment (in the induction or maintenance studies) and meet (NCT03627091), completed the ET or Week 52 visit in maintenance study SHP647-307, had - Participants must have been enrolled previously in Study SHP647-305 (NCT03559517) or.- Participants receiving any treatment(s) for UC are eligible provided they have been onĪ stable dose for the designated period of time.The baseline value for induction studies. Or a subscore for RB or=30% and >or=3 points compared to Points and >or=30%, with an accompanying decrease in the subscore for RB >or=1 point Study ET or Week 52 visit: i) Clinical composite score that has decreased by >or=2 Participants have received ontamalimab at the maintenance Received ontamalimab in the induction studies and fulfilled the maintenance study Participants are on placebo at the maintenance study ET or Week 52 visit: they Maintenance studies), and meet one of the following criteria: (NCT03290781), had responded to ontamalimab treatment (in the induction and/or SHP647-302 (NCT03259308), and are in the treatment period of Study SHP647-303,Ĭompleted the early termination (ET) or Week 52 visit in maintenance study SHP647-303
- Participants must have been enrolled previously in study SHP647-301 (NCT03259334),.(personally or via a legally authorized representative) informed consent and/orĪssent, as applicable, to participate in the study. - Participants must be able to voluntarily provide written, signed, and dated.Understanding, ability, and willingness to fully comply with study procedures and - Participants and/or their parent or legally authorized representative must have an.Participants with Ulcerative Colitis (UC):
0 kommentar(er)
